^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imprime PGG (odetiglucan)

    i
    Other names: BTH-1677, BTH1677, 1,3-1,6 beta glucan, soluble beta glucan, B-glucan PGG, PGG glucan, PGG beta-glucan
    Associations

    News

    Trials
    Company:
    HiberCell
    Drug class:
    Macrophage modulator, Dectin-1 agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)
    3ms
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, University of Pennsylvania
    New P2 trial
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)
    3ms
    Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov)
    P2, N=27, Recruiting, Abramson Cancer Center at Penn Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
    5ms
    Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Abramson Cancer Center at Penn Medicine
    New P2 trial
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
    9ms
    Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma (clinicaltrials.gov)
    P1/2, N=32, Completed, HiberCell, Inc. | Phase classification: P1b --> P1/2 | N=48 --> 32
    Phase classification • Enrollment change
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Imprime PGG (odetiglucan)
    over1year
    Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 (clinicaltrials.gov)
    P1/2, N=35, Completed, Lawrence Feldman, MD | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
    over1year
    A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=5, Terminated, HiberCell, Inc. | N=45 --> 5 | Trial completion date: Apr 2027 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Mar 2024; sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    CDX-1140 • Imprime PGG (odetiglucan)
    over2years
    A Maintenance Therapy Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=45, Recruiting, HiberCell, Inc. | N=30 --> 45 | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    CDX-1140 • Imprime PGG (odetiglucan)
    over2years
    Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) (clinicaltrials.gov)
    P2, N=26, Completed, HiberCell, Inc. | Active, not recruiting --> Completed | N=50 --> 26 | Trial completion date: Jan 2027 --> Apr 2023 | Trial primary completion date: Jan 2025 --> Mar 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • CD86 (CD86 Molecule)
    |
    PIK3CA mutation
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
    over2years
    A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy. (ASCO 2023)
    5 US sites will participate. Clinical trial information: NCT04834778.
    Clinical • P1 data • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    CDX-1140 • Imprime PGG (odetiglucan)
    almost3years
    Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, HiberCell, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • CD86 (CD86 Molecule)
    |
    PIK3CA mutation
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
    over3years
    Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, Lawrence Feldman, MD | Trial completion date: Sep 2021 --> Oct 2025 | Trial primary completion date: Sep 2020 --> Jun 2022
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)